Deals In Depth: January 2023

Eight $1bn+ alliances were penned in January. Topping the list was a potential $4.4bn deal between Neurocrine Biosciences and Voyager Therapeutics to advance multiple gene therapies for the treatment of neurological diseases.

Deals In Depth

With eight $1bn+ alliances inked in January, topping the list was a potential $4.4bn deal between Neurocrine Biosciences and Voyager Therapeutics to advance multiple gene therapies for the treatment of neurological diseases. Neurocrine Biosciences, Inc. receives worldwide R&D, manufacturing, and commercialization rights to Voyager Therapeutics, Inc’s GBA1 gene therapy program directed to the gene that encodes glucosylceramidase beta 1 for Parkinson’s disease as well as three new gene therapy programs directed to rare CNS targets. (Also see "Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players" - Scrip, 11 January, 2023.)

In the top January M&A by deal value, AstraZeneca PLC agreed to acquire CinCor Pharma, Inc. for a...

More from Deal-Making

More from In Vivo